Form 4: Rocket Pharmaceuticals Director Granted 30,000 Restricted Stock Units

Carsten Boess, a Director at Rocket Pharmaceuticals, Inc., was granted 30,000 restricted stock units, aligning his interests with shareholders.

Summary

• Carsten Boess, a Director of Rocket Pharmaceuticals, Inc. (RCKT), acquired 30,000 restricted stock units (RSUs).
• The transaction date for this acquisition was June 18, 2025.
• These RSUs convert to common stock on a one-for-one basis and were granted at a price of $0.
• The RSUs are scheduled to vest in full on June 18, 2026.
• Following this transaction, Carsten Boess beneficially owns 30,000 common shares indirectly through these RSUs.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive signal, aligning management's interests with shareholders and indicating continued commitment. It's a standard compensation practice.

Positives

• The grant of 30,000 restricted stock units to Director Carsten Boess aligns his financial interests directly with those of the company's shareholders.
• Equity compensation at a $0 price is a common and effective way to incentivize long-term performance and retention of key personnel.

Negatives

• No immediate cash proceeds for the director from this grant, as it is equity compensation that vests over time.

Risks

• The value of the restricted stock units is subject to the future market price fluctuations of Rocket Pharmaceuticals, Inc.'s common stock.
• The RSUs will only convert to common stock upon vesting, which is contingent on the director's continued service until June 18, 2026.

Future Outlook

The 30,000 restricted stock units granted to Director Carsten Boess are scheduled to vest in full on June 18, 2026, contingent on his continued service.

Industry Context

This transaction represents a standard practice of equity-based compensation for directors in the biotechnology and pharmaceutical industry, aiming to align leadership incentives with long-term company performance and shareholder value creation.

Stakeholder Impact

• Shareholders: Positive, as the director's interests are further aligned with shareholder value creation through equity ownership.
• Employees: No direct impact mentioned, but it reinforces the company's compensation philosophy.

Next Steps

• Vesting of the 30,000 restricted stock units on June 18, 2026.

Key Dates

Keywords

Rocket Pharmaceuticals, RCKT, SEC Form 4, Insider Trading, Restricted Stock Units, RSUs, Equity Compensation, Director Compensation, Beneficial Ownership